The BNT162b2 vaccine (Pfizer–BioNTech) has U.S. licensure for immunization against Covid-19 in persons 12 years of age or older and emergency use authorization in children 5 to 11 years of age ...

On the basis of safety and immunogenicity results in part 1 of the trial, the 25-μg dose was evaluated in part 2. In part 2, 3040 children 2 to 5 years of age and 1762 children 6 to 23 months of ...

Mentavi’s innovative online asynchronous assessment, validated in a clinical study presented at the 10th World Congress on ...

More information: Hiroya Nishida et al, Evaluation of the Diagnostic Criteria for Anti-NMDA Receptor Encephalitis in Japanese Children, Neurology (2021). DOI: 10.1212/WNL.0000000000011789.